NervGen Names Adam Rogers CEO, Grants 717,891 Options at US$5.06 and US$5.57
NervGen board unanimously appointed Adam Rogers as CEO after his tenure as interim CEO delivered the Nasdaq listing and advanced NVG-291 toward late-stage development. The company granted him 717,891 stock options exercisable at US$5.06 and US$5.57 per share, vesting over four years to align leadership incentives with long-term growth.
1. CEO Appointment
NervGen’s Board of Directors has unanimously appointed Adam Rogers, MD, as President and Chief Executive Officer, effective immediately. The decision follows Rogers’ interim leadership, reflecting the board’s confidence in his ability to execute the company’s mission in spinal cord injury therapeutics.
2. Interim Milestones
During his interim tenure, Rogers oversaw the company’s successful Nasdaq listing and positioned NVG-291 for late-stage development. His dual expertise as a practicing physician and biotech executive drove decisive progress against key R&D and regulatory milestones.
3. Option Grants and Vesting
In connection with his appointment, Rogers received 717,891 stock options, with 614,799 exercisable at US$5.06 per share for ten years and 103,092 exercisable at US$5.57 per share for five years. The options vest 25% after one year and monthly over the following 36 months, aligning his incentives with long-term value creation.